Immunologix and GenScript have entered into a strategic partnership to offer a complete platform for producing human antibody therapeutics.

The partnership will combine Immunologix’s proprietary technique for producing fully human antibodies with GenScript’s antibody drug development service platform.

The two companies will offer an integrated platform for the discovery and development of full human therapeutic antibody candidates ready for clinical trials.

GenScript vice-president Dr Nick Yan said the partnership could offer clients one-stop solutions and complete portfolios, covering all their needs in human therapeutic antibody from target identification to clinic candidates in a cost-effective and time-efficient manner.